Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine versus azacitidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS
2010-018467-42Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Overall survival at three years. Started Oct 2010; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-018467-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018467-42.